<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Photodynamic therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Photodynamic therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Photodynamic therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Edward V Maytin, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christine B Warren, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Craig A Elmets, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 20, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4096647797">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Photodynamic therapy (PDT) is a two-step treatment in which a drug that acts as a photosensitizer is administered to specifically target a diseased tissue of interest, followed by illumination with visible light to activate the drug and destroy the target tissue [
         <a href="#rid1">
          1
         </a>
         ]. PDT was developed primarily for treatment of cancer and precancers. While PDT has been used to treat internal cancers in many parts of the body by administering a systemic photosensitizer and delivering light through an optical fiber, by far the most common application of PDT in clinical medicine is for treatment of cancer and precancer of the skin [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         This topic will review the principles and practical applications of PDT for treating neoplastic and preneoplastic conditions of the skin. The use of PDT in oncology and internal medicine is discussed in specific topic reviews.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2494.html" rel="external">
          "Management of superficial esophageal cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4382.html" rel="external">
          "Endobronchial photodynamic therapy in the management of airway disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3578459214">
         <span class="h1">
          PRINCIPLES AND MECHANISMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nearly all drugs used for PDT are derivatives of heme (porphyrins), large tetrapyrrole molecules produced in the mitochondria of all cells. Porphyrins are products of a well-known biochemical pathway, catalyzed by eight enzymes that can be genetically disrupted in the various forms of hereditary porphyria  (
         <a class="graphic graphic_figure graphicRef117995" href="/z/d/graphic/117995.html" rel="external">
          figure 1
         </a>
         ). Thus, PDT can be considered a form of "artificial porphyria." (See
         <a class="medical medical_review" href="/z/d/html/7101.html" rel="external">
          "Porphyrias: An overview"
         </a>
         .)
        </p>
        <p>
         Because porphyrins are conjugated (containing multiple double bonds), they can absorb visible wavelengths of light very efficiently and convert the energy into chemical reactions [
         <a href="#rid1">
          1
         </a>
         ]. Historically, the earliest PDT drugs for medical use were derived from hemoglobin (eg, hematoporphyrin derivative, benzoporphyrin derivative) and other compounds with structural similarities to heme [
         <a href="#rid3">
          3
         </a>
         ]. However, in dermatology, the use of such preformed photosensitizers has been largely replaced by prodrugs that represent the second step in the porphyrin synthesis pathway, namely 5-aminolevulinic acid (ALA) or an esterified form,
         <a class="drug drug_general" data-topicid="16481" href="/z/d/drug information/16481.html" rel="external">
          methyl aminolevulinate
         </a>
         (MAL)  (
         <a class="graphic graphic_figure graphicRef113765 graphicRef113767" href="/z/d/graphic/113765.html" rel="external">
          figure 2A-B
         </a>
         ).
        </p>
        <p>
         ALA or MAL are applied topically, taken up by neoplastic cells, and converted into various porphyrins; protoporphyrin IX (PPIX) is the form that absorbs light most efficiently. This approach to PDT works because ALA bypasses the first (inhibitory) feedback step in the heme synthesis pathway, thus allowing PPIX to accumulate to very high levels  (
         <a class="graphic graphic_figure graphicRef113765" href="/z/d/graphic/113765.html" rel="external">
          figure 2A
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Most uses of PDT involve the topical application of ALA or MAL to the skin for several hours to allow the buildup of PPIX within target cancer or precancer cells, followed by illumination with a prescribed amount of light (delivered from an approved broadband lamp or a laser) to activate the PPIX. The photoactivation of PPIX, in the presence of oxygen, causes free radical-based photochemical reactions within mitochondria and surrounding membranes, ultimately leading to the death of the target cells. To achieve good photoactivation, the chosen light source must emit sufficient energy at wavelengths that correspond to major peaks in the absorption spectrum of PPIX. Typically, 400 nm (blue) or 635 nm (red) are chosen  (
         <a class="graphic graphic_figure graphicRef113767" href="/z/d/graphic/113767.html" rel="external">
          figure 2B
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3059112246">
         <span class="h1">
          CELLULAR EFFECTS OF PHOTODYNAMIC THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Perhaps the most important principle in PDT is its high selectivity for neoplastic cells and tissues. Even when the prodrug is applied over a very broad area of skin, cancerous or precancerous cells accumulate far more protoporphyrin IX (PPIX) than do normal epidermal cells for two reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher rates of
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         uptake
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher rates of synthesis and accumulation of PPIX within the mitochondria
        </p>
        <p>
        </p>
        <p>
         Reasons for the last include tumor-selective changes in expression and/or activity of critical enzymes within the heme synthesis pathway [
         <a href="#rid5">
          5
         </a>
         ]. The selective PPIX accumulation in tumor tissue in vivo, relative to surrounding normal skin, has been clearly demonstrated using animal models of squamous cell carcinoma [
         <a href="#rid6">
          6
         </a>
         ], squamous precarcinoma [
         <a href="#rid7">
          7
         </a>
         ], and basal cell carcinoma [
         <a href="#rid8">
          8
         </a>
         ], as well as by noninvasive PPIX measurements in human actinic keratoses [
         <a href="#rid9">
          9
         </a>
         ]. Upon illumination, the consequence of the selectively higher target PPIX levels is preferential photodestruction of the cancer tissue relative to neighboring normal skin cells [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Early research in PDT focused on the physical and biochemical mechanisms by which PDT kills cancer cells, with an assumption that high intracellular PPIX levels and a high light intensity (fluence rate) are necessary for good tumor killing [
         <a href="#rid3">
          3
         </a>
         ]. However, in vivo investigations and clinical experience show that both lower PPIX and light intensities also work quite well, suggesting that previously unrecognized mechanisms as well as the participation of the immune system may be critical for generating a therapeutic response to PDT. (See
         <a class="local">
          'Variations on the standard photodynamic therapy regimen'
         </a>
         below.)
        </p>
        <p>
         One important consequence of the mitochondrial membrane-targeted mechanism by which PDT kills neoplastic cells is that PDT is nonmutagenic. This gives PDT a distinct advantage over DNA-targeting modalities because, unlike ionizing radiation or many chemotherapeutic agents, PDT can be performed multiple times without fear of introducing oncogenic DNA mutations. Another advantage of PDT is the fact that treated lesions heal without a scar, perhaps due to suppressive effects upon fibroblasts [
         <a href="#rid11">
          11,12
         </a>
         ]. Thus, PDT should be considered a nonscarring treatment option for patients who develop frequent nonmelanoma skin cancers and precancers.
        </p>
        <p class="headingAnchor" id="H1136151401">
         <span class="h1">
          LIGHT SOURCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The types of visible light that can be used for PDT of the skin are surprisingly varied and include various coherent light sources (lasers and light-emitting diodes), incoherent sources (broadband lamps), and natural sunlight (see
         <a class="local">
          'Variations on the standard photodynamic therapy regimen'
         </a>
         below). However, efficacy and safety are critical in PDT, and therefore, only validated light sources can be recommended. In the United States, two broadband light sources that target the major absorption peaks of protoporphyrin IX  (
         <a class="graphic graphic_figure graphicRef113767" href="/z/d/graphic/113767.html" rel="external">
          figure 2B
         </a>
         ) are approved by the US Food and Drug Administration (FDA):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A blue light source (BLU-U Blue Light Photodynamic Therapy Illuminator 400 nm), to be used with the proprietary
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         (ALA) 20% solution (Levulan Kerastick)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A red light source (BF-RhodoLED 635 nm), to be used with the proprietary ALA 10% nanoemulsion (Ameluz)
        </p>
        <p>
        </p>
        <p>
         These light sources should be used exclusively with the companion prodrug for which the drug/light combination was tested in the original clinical trials [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
         Although clinicians may use other light sources, the results are not always predictable. Importantly, medical insurance companies often will not reimburse for treatment sessions with drugs or light sources that were not FDA approved.
        </p>
        <p class="headingAnchor" id="H3422737877">
         <span class="h1">
          TOPICAL PHOTOSENSITIZING MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two drug/light combinations are approved by the US Food and Drug Administration (FDA) for treatment of nonhyperkeratotic actinic keratosis (AK) of the face and scalp:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          Aminolevulinic acid
         </a>
         (ALA) 20% solution (Levulan Kerastick), a liquid that is allowed to dry on the skin and is then activated using the proprietary blue light source (BLU-U 400 nm) [
         <a href="#rid13">
          13
         </a>
         ]. This drug/light combination is widely available in the United States but not in Europe or Canada.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ALA 10% nanoemulsion (Ameluz), a gel that must be covered with an occlusive dressing and later activated using the proprietary red light (BF-RhodoLED 635 nm) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In 2018, ALA 20% solution (Levulan Kerastick) has also been approved by the US FDA for the treatment of AKs of the upper extremities [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         The ALA 10% nanoemulsion was developed in Europe, where it is approved for PDT in combination with red light for the treatment of mild and moderate AK.
        </p>
        <p>
         Another agent,
         <a class="drug drug_general" data-topicid="16481" href="/z/d/drug information/16481.html" rel="external">
          methyl aminolevulinate
         </a>
         (MAL) 16.8% cream (Metvix) used with red light, is available in Europe, Canada, Australia, and other countries, but not in the United States, for the treatment of nonhyperkeratotic AK, superficial and nodular basal cell carcinoma, and squamous cell carcinoma in situ [
         <a href="#rid16">
          16
         </a>
         ]. However, the approval may vary among countries.
        </p>
        <p class="headingAnchor" id="H1221796994">
         <span class="h1">
          CLINICAL INDICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3513629601">
         <span class="h2">
          Approved indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         PDT is approved by the US Food and Drug Administration (FDA) for the treatment of thin, nonhyperkeratotic actinic keratosis (AK) [
         <a href="#rid17">
          17
         </a>
         ]. In Europe [
         <a href="#rid16">
          16
         </a>
         ], Canada, Australia, and other countries worldwide, PDT is also approved by the local regulatory authorities for the treatment of superficial and thin nodular basal cell carcinoma (BCC), when other available therapies are not acceptable (either due to possible morbidity or poor cosmetic outcome), and squamous cell carcinoma (SCC) in situ (Bowen disease). However, the approval may vary among countries.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Actinic keratosis
         </strong>
         – In an earlier phase III trial of 20%
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         (ALA) solution incubated for 14 to 18 hours without occlusion in conjunction with blue light, 73 percent of subjects had 100 percent AK clearance at 12 weeks [
         <a href="#rid13">
          13
         </a>
         ]. Shorter incubation times are used in clinical practice, based upon a series of studies showing similar efficacy despite this modification [
         <a href="#rid9">
          9,18,19
         </a>
         ]. In the European phase III trial of 10% ALA nanoemulsion gel incubated for three hours after removal of scales/crusts and occlusion, in conjunction with red light, 91 percent of subjects had 100 percent AK clearance at 12 weeks [
         <a href="#rid14">
          14
         </a>
         ]. The efficacy of PDT for the treatment of AK has been confirmed by multiple randomized trials and two meta-analyses [
         <a href="#rid20">
          20,21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">
          "Treatment of actinic keratosis", section on 'Photodynamic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basal cell carcinoma
         </strong>
         – Superficial BCC lesions appear to be most responsive to therapy, with sustained response rates ranging from 72 to 97 percent [
         <a href="#rid22">
          22-27
         </a>
         ]. Nodular BCCs are less likely than superficial BCCs to respond to treatment with PDT, with sustained response rates of 33 to 76 percent [
         <a href="#rid22">
          22,28-30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence", section on 'Photodynamic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Given the numerous BCCs that arise in patients with basal cell nevus syndrome, efforts are being made to optimize PDT so that it can be used as a noninvasive treatment option for both children and adults with this genetic disease [
         <a href="#rid31">
          31-36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5340.html" rel="external">
          "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Squamous cell carcinoma in situ (Bowen disease)
         </strong>
         – In patients with SCC in situ, studies have demonstrated initial clearance rates of 88 to 100 percent at three months and sustained clearance of 68 to 89 percent at one and a half to four years after one to two cycles of
         <a class="drug drug_general" data-topicid="16481" href="/z/d/drug information/16481.html" rel="external">
          methyl aminolevulinate
         </a>
         (MAL)-PDT [
         <a href="#rid37">
          37-40
         </a>
         ]. A randomized study comparing MAL-PDT with placebo-PDT, cryotherapy, or topical 5-fluoruracil (5-FU) for the treatment of SCC in situ found that MAL-PDT was superior in efficacy to 5-FU and placebo-PDT and was less painful than cryotherapy [
         <a href="#rid37">
          37
         </a>
         ]. After a single session of ALA-PDT, only 53 percent of patients were reported to still be clear at five years [
         <a href="#rid41">
          41
         </a>
         ]. Therefore, repeated sessions and monitoring should be considered as part of the treatment plan. PDT is not recommended for invasive SCCs due to poor clearance rates and metastatic potential [
         <a href="#rid39">
          39,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H480354976">
         <span class="h2">
          Off-label use
         </span>
         <span class="headingEndMark">
          —
         </span>
         PDT has been increasingly used off label for the treatment of a variety of neoplastic and non-neoplastic skin conditions. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acne vulgaris
         </strong>
         – The use of blue light alone, without a topical photosensitizer, is FDA approved for the treatment of moderate inflammatory acne vulgaris [
         <a href="#rid43">
          43
         </a>
         ].
         <em>
          Propionibacterium acnes
         </em>
         produce porphyrins as part of their normal metabolism, which allows a direct photodynamic effect. ALA application prior to illumination with blue or red light has been reported to improve outcomes [
         <a href="#rid44">
          44-48
         </a>
         ]. The duration of acne remission after PDT appears to be extended with longer incubation times (at least three hours) and the use of red light [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/37.html" rel="external">
          "Light-based, adjunctive, and other therapies for acne vulgaris"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Photorejuvenation
         </strong>
         – In addition to AK clearance on photodamaged skin, PDT also exerts photorejuvenating effects [
         <a href="#rid50">
          50
         </a>
         ]. It can lessen the appearance of fine lines and uneven skin tone, as well as improve skin texture. Intense pulsed light devices are most commonly used in combination with topical ALA for this cosmetic treatment [
         <a href="#rid51">
          51-53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13645.html" rel="external">
          "Nonablative skin resurfacing for skin rejuvenation", section on 'Photodynamic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other off-label indications are summarized in the table  (
         <a class="graphic graphic_table graphicRef113758" href="/z/d/graphic/113758.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3268864624">
         <span class="h1">
          STANDARD PHOTODYNAMIC THERAPY REGIMENS FOR ACTINIC KERATOSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         PDT protocols vary depending on the photosensitizer used. Modifications may be needed to enhance the therapeutic response. (See
         <a class="local">
          'Variations on the standard photodynamic therapy regimen'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1113782406">
         <span class="h2">
          Before initiating treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to initiating treatment with PDT, it is important to review the patient's medical history, educate the patient on appropriate post-treatment care, and obtain an informed consent:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review the patient's medical history, medication list, and allergies to ensure no contraindications to PDT (see
         <a class="local">
          'Contraindications to photodynamic therapy'
         </a>
         below). Ask whether the patient has a history of recurrent herpes labialis and consider providing antiviral prophylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Confirm that the patient understands the requirement to avoid sunlight and bright indoor lights for 48 hours after the procedure and explain the "sunburn-like" appearance of the skin expected for several days after treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain verbal or written informed consent to proceed with the treatment.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2655788879">
         <span class="h2">
          Photodynamic therapy administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The administration of PDT involves the following steps:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Degrease the skin to be treated with an ethanol or acetone pad.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If using
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         (ALA) 10% nanoemulsion, scales will need to be gently removed prior to gel application. Avoid the induction of bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When applying the topical photosensitizing drug, wear
         <strong>
          nitrile
         </strong>
         gloves. Adequate protection is not provided by vinyl and latex gloves.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apply topical photosensitizer to individual skin lesions or to an area of skin (if field therapy is desired). Refer to package insert for specific application instructions for each product (such as desired thickness of gel or maximum amount of product to be used during a treatment session) [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If necessary, cover with an occlusive, nonabsorbent dressing. Occlusion is not required when using ALA 20% solution on face or scalp but is used when using topical ALA 10% nanoemulsion. Occlusion is indicated when using ALA 20% solution on upper extremities [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Incubation time when using ALA 20% solution typically varies from zero to six hours and is determined by the treating clinician. In the US Food and Drug Administration (FDA) prescribing information, the incubation times for ALA 20% solution are 14 to 18 hours for scalp or face and 3 hours for upper extremities, with occlusion. ALA 10% nanoemulsion incubation time is three hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a gel is used, it must be wiped away with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         and gauze prior to illumination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have the patient sit comfortably in a chair or recline on an exam table in preparation for illumination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Position lamp over treatment area, approximately two to four inches from the skin. Reference package insert [
         <a href="#rid43">
          43,56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During illumination, the patient and provider must wear appropriate eye protection. The patient should not stare into the light and may be most comfortable with their eyes closed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Standard total light dose delivered when using ALA 20% solution with blue light (417±5 nm) is 10 J/cm
         <sup>
          2
         </sup>
         , which requires 16 minutes and 40 seconds of illumination time with the BLU-U Blue Light Photodynamic Therapy Illuminator 400 nm light source [
         <a href="#rid43">
          43
         </a>
         ]. The dose when using ALA 10% nanoemulsion with red light (635±9 nm) is 37 J/cm
         <sup>
          2
         </sup>
         , which takes approximately eight minutes with the BF-RhodoLED 635 nm light source [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="local">
          'Light sources'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The light operator should stay with the patient during illumination to assist with any pain-relieving measures required during the treatment. (See
         <a class="local">
          'Pain control measures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gently wash off treatment area at the end of the session and apply a physical sunscreen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review and provide written aftercare instructions. Optional prescriptions include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Short course of oral antiviral agent for herpes labialis prophylaxis in patients with history of recurrent herpes simplex virus.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Small quantity of low-to-medium strength topical steroid ointment  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 2
         </a>
         ) for application during first few days post-treatment to help reduce pain and inflammation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depending on the severity of the actinic keratosis (AK), a second session may be scheduled in four to eight weeks. Otherwise, a follow-up visit in three months is recommended to assess AK clearance.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1104456584">
         <span class="h1">
          VARIATIONS ON THE STANDARD PHOTODYNAMIC THERAPY REGIMEN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since the first US Food and Drug Administration (FDA) approval of a PDT regimen for actinic keratoses (AKs) in 1999, many studies have focused on improving the efficacy of PDT and reducing the inflammatory side effects. Such efforts have included measures to increase prodrug uptake, improve protoporphyrin IX (PPIX) accumulation, and reduce the pain that patients experience during illumination. (See
         <a class="local">
          'Pain control measures'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4047078150">
         <span class="h2">
          Modifications to increase drug uptake
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Curettage
         </strong>
         – The gentle removal of scales and crust on AK lesions is recommended in the protocol for
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         (ALA) 10% nanoemulsion and for
         <a class="drug drug_general" data-topicid="16481" href="/z/d/drug information/16481.html" rel="external">
          methyl aminolevulinate
         </a>
         (MAL) in Europe and Canada [
         <a href="#rid55">
          55,57
         </a>
         ]. For AK lesions on the scalp, abrading the lesions with fine sandpaper prior to application of ALA 20% solution followed by blue light improves the AK lesion clearance rate by an average of 55 percent [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microneedling
         </strong>
         – The use of a roller with microneedles can improve prodrug uptake and clinical response and reduce the incubation time [
         <a href="#rid59">
          59-62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fractional lasers
         </strong>
         – The use of an ablative fractional laser can increase ALA or MAL penetration and improve the efficacy of PDT [
         <a href="#rid63">
          63,64
         </a>
         ]. A study evaluating the effects of curettage, microneedling, microdermabrasion, and laser ablation prior to PDT found a significant increase in intraepidermal PPIX accumulation after each intervention compared with no pretreatment [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13648.html" rel="external">
          "Principles of laser and intense pulsed light for cutaneous lesions", section on 'Ablative'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Occlusion
         </strong>
         – An occlusive dressing, to increase drug penetration prior to illumination, has been shown to increase AK clearance rates, whether the prodrug is 5-ALA 20% liquid [
         <a href="#rid66">
          66
         </a>
         ], ALA 10% nanoemulsion [
         <a href="#rid14">
          14
         </a>
         ], or MAL 16.8% cream [
         <a href="#rid18">
          18,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thermal effects
         </strong>
         – It has been shown that mild local hyperthermia (raising the skin temperature to 40 to 42°C) increases PPIX synthesis and enhances the therapeutic response of AK to PDT [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1987201476">
         <span class="h2">
          Modifications to increase protoporphyrin IX synthesis and accumulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long ALA incubation times are known to enhance PPIX accumulation, with maximal PPIX levels at 14 to 18 hours [
         <a href="#rid54">
          54
         </a>
         ]. An iron chelator, such as
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          deferoxamine
         </a>
         , inhibits ferrochelatase (the last enzyme in the heme pathway) and thereby enhanced PPIX accumulation in animal and pilot human studies [
         <a href="#rid70">
          70,71
         </a>
         ]. Other studies in animal models and small human studies have shown that pretreatment with several common drugs, including
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid72">
          72
         </a>
         ], vitamin D [
         <a href="#rid6">
          6
         </a>
         ], and topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [
         <a href="#rid7">
          7,73
         </a>
         ], causes a prodifferentiation response in squamous cancer cells that enhances PPIX accumulation and improves PDT efficacy.
        </p>
        <p>
         In a small split-body trial including 17 patients with AK, pretreatment of lesions on one side of the body with topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         for six days prior to applying MAL cream increased the level of PPIX by two- to threefold, as well as p53 induction, compared with non-pretreated lesions [
         <a href="#rid73">
          73
         </a>
         ]. Clearance rates after PDT with or without topical fluorouracil pretreatment were 75 versus 45 percent at three months and 67 versus 39 percent at six months, respectively.
        </p>
        <p>
         In another study, it was shown that pretreatment with high-dose oral vitamin D taken at home for five days prior to blue light PDT with short or no incubation ("in-office painless PDT") significantly increases AK lesion clearance outcomes [
         <a href="#rid74">
          74
         </a>
         ]. (See
         <a class="local">
          'Pain relief during treatment'
         </a>
         below.)
        </p>
        <p>
         Recommendation about the use of these combination regimens must await the results of larger clinical trials.
        </p>
        <p class="headingAnchor" id="H887219095">
         <span class="h2">
          Short-contact photodynamic therapy regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because patients frequently experience stinging pain when light is administered after long PDT prodrug incubation times (eg, 14 to 18 hours after ALA 20% solution application), clinicians have tried shorter incubation times in an attempt to reduce this adverse effect. PPIX was shown to accumulate in the skin with linear kinetics, even during the first two-hour, post-ALA application [
         <a href="#rid9">
          9
         </a>
         ], so many clinicians now routinely apply ALA 20% solution for a one-to-two-hour incubation period prior to blue light exposure. A study comparing ALA incubation times of one, two, or three hours found very similar therapeutic efficacy with all three conditions [
         <a href="#rid18">
          18
         </a>
         ]. Other reports have used even shorter incubation times but with a relatively long duration of light exposure. These "in-office painless PDT" regimens have proven effective for AK of the face and scalp [
         <a href="#rid75">
          75-77
         </a>
         ]. (See
         <a class="local">
          'Pain relief during treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1939178855">
         <span class="h2">
          Daylight photodynamic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 2008, a group of Danish investigators published a study showing that natural sunlight can be used to activate PPIX in AK lesions, a technique known as "daylight PDT" [
         <a href="#rid78">
          78
         </a>
         ]. With this regimen, MAL is applied and then patients are sent outside in the sun for approximately two hours. Postillumination erythema and lesion clearance rates are similar to those seen with artificial light sources. Interestingly, patients experience very little pain with daylight PDT. Many subsequent trials have confirmed these findings [
         <a href="#rid79">
          79
         </a>
         ]. While advantages of daylight PDT include low cost and reduced pain, exposure to ultraviolet B wavelengths may raise some concern. Also, the technique should be viewed with caution in parts of the world where solar irradiance is very intense, creating a potential safety issue. Although daylight PDT was originally developed using MAL, protocols employing ALA 20% solution have also been developed [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">
          "Treatment of actinic keratosis", section on 'Daylight photodynamic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H543798935">
         <span class="h1">
          SAFETY MEASURES
         </span>
        </p>
        <p class="headingAnchor" id="H1702358802">
         <span class="h2">
          Eye protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinal damage from the visible light spectrum has been described and may play a role in age-related macular degeneration [
         <a href="#rid81">
          81-83
         </a>
         ]. Therefore, appropriate goggles that block either blue or red light should be worn by the patient throughout illumination. The patient must be advised not to stare directly into the light. Likewise, it is recommended that any other individuals in the room during treatment wear protective eyewear.
        </p>
        <p class="headingAnchor" id="H74483165">
         <span class="h2">
          Use of other photosensitizing agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although only visible light is used during PDT, an exacerbated reaction could possibly occur when a PDT patient is concurrently taking a medication known to be phototoxic in the setting of ultraviolet A light exposure [
         <a href="#rid84">
          84
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">
          "Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Drug-induced'
         </a>
         .)
        </p>
        <p>
         It is commonly recommended that
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         antibiotics be stopped one to two weeks prior to PDT, if possible. Retinoids should also be temporarily discontinued prior to PDT, as they can exacerbate post-PDT inflammatory reactions. Examples of other photosensitizing medications to consider stopping temporarily are thiazide diuretics,
         <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">
          griseofulvin
         </a>
         , phenothiazines, fluoroquinolones, St. John's wort, sulfonylureas, sulfonamides, and nonsteroidal anti-inflammatory drugs [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3719919572">
         <span class="h1">
          SHORT- AND LONG-TERM ADVERSE EFFECTS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Temporary photosensitivity to light in areas to which the topical photosensitizer is applied is an expected and desired effect; this photosensitivity can remain up to 48 hours after the treatment, which is why total sun avoidance for 48 hours is mandatory.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient, amnestic episodes have been reported during postmarketing use of
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         (ALA) 20% solution (Levulan Kerastick) in combination with BLU-U Blue Light Photodynamic Therapy Illuminator [
         <a href="#rid85">
          85
         </a>
         ]. (See
         <a class="local">
          'Topical photosensitizing medications'
         </a>
         above and
         <a class="local">
          'Light sources'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition to temporary pain (see
         <a class="local">
          'Pain control measures'
         </a>
         below), a localized, erythematous reaction can typically be expected for four to seven days and may be accompanied by a tingling or burning sensation, edema, minute vesicles, or crusting. After the erythematous reaction, the patient may experience exfoliation and pruritus of the skin for up to a week, which should be treated with soothing, bland emollients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sterile pustule development has been described following PDT. If pustules are persistent, painful, or worsen when healing would be expected, consider testing for a possible
         <em>
          Staphylococcus aureus
         </em>
         or methicillin-resistant
         <em>
          S. aureus
         </em>
         superinfection [
         <a href="#rid86">
          86,87
         </a>
         ]. This complication can sometimes arise in men who shave their faces with a contaminated razor or in immunosuppressed patients. (See
         <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flares of herpes labialis after PDT have been observed in patients with a history of recurrent cold sores. A prescription for a prophylactic antiviral (eg,
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         1 g/day for five days) may be considered for patients with frequent flares, especially when treating actinic cheilitis [
         <a href="#rid88">
          88
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8287.html" rel="external">
          "Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults", section on 'Prophylaxis for recurrent HSV with identified trigger'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypo- or hyperpigmentation is uncommon but can occur in darker skin types [
         <a href="#rid86">
          86,89
         </a>
         ]. As with other types of postinflammatory hypo- or hyperpigmentation, it may take many weeks to resolve.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contact allergy is rare but can occur if the patient is allergic to the active or inactive ingredients in the topical photosensitizer. For ALA 10% nanoemulsion product, inactive ingredients include
         <a class="drug drug_general" data-topicid="120131" href="/z/d/drug information/120131.html" rel="external">
          sodium benzoate
         </a>
         , soybean phosphatidylcholine, and propylene glycol [
         <a href="#rid55">
          55
         </a>
         ]. For ALA 20% solution, inactive ingredients include alcohol USP (ethanol content = 48 percent volume/volume), water, laureth-4, isopropyl alcohol, and polyethylene glycol [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Scarring is rare. In fact, PDT has been used to improve the appearance of hypertrophic scars. The mechanism is thought to involve the inhibition of collagen synthesis and induction of matrix metalloproteinases [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2388514689">
         <span class="h1">
          PAIN CONTROL MEASURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pain associated with PDT is a short-term side effect, but it is one of the limiting factors in delivering this noninvasive therapy for skin disease [
         <a href="#rid90">
          90
         </a>
         ]. Pain is experienced during illumination and/or post-treatment and can be intense for some patients. Research on the mechanism of pain during the illumination phase of PDT suggests that receptor channels (transient receptor potential ankyrin type 1 and transient receptor potential vanilloid type 1) may be involved. These channels are expressed in the nerve endings of pain fibers and become stimulated when protoporphyrin IX (PPIX), which accumulates in nearby cancer cells and then diffuses into nearby nerves, is activated by exposure to light [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         Pain perception varies among individuals but is usually more severe when treating large treatment areas and/or highly photodamaged skin of the face or scalp [
         <a href="#rid92">
          92,93
         </a>
         ]. Anecdotally, patients tend to experience more pain with red light than with blue light PDT, and lower pain scores have been seen with shorter wavelengths of light, such as green light, compared with red light [
         <a href="#rid94">
          94,95
         </a>
         ]. It is debated whether
         <a class="drug drug_general" data-topicid="16481" href="/z/d/drug information/16481.html" rel="external">
          methyl aminolevulinate
         </a>
         (MAL) is less painful than
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         (ALA) [
         <a href="#rid96">
          96-99
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3420890497">
         <span class="h2">
          Pain relief during treatment
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distraction methods
         </strong>
         – Conversation or individualized music are often welcomed methods of distraction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cooling
         </strong>
         – Cold air/mist/compresses have been reported to be one of the most effective ways to reduce, but not eliminate, the pain associated with PDT [
         <a href="#rid90">
          90,100,101
         </a>
         ]. Unfortunately, cooling the treatment area may result in lower PPIX photobleaching and, hence, could negatively affect PDT outcome [
         <a href="#rid102">
          102
         </a>
         ]. Therefore, cooling devices should be used briefly and only as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical anesthetics
         </strong>
         – No benefit was shown with the use of the following topical anesthetics for pain associated with PDT:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         EMLA (
         <strong>
          e
         </strong>
         utectic
         <strong>
          m
         </strong>
         ixture of
         <strong>
          l
         </strong>
         ocal
         <strong>
          a
         </strong>
         nesthetics, containing 2.5%
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         and 2.5%
         <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">
          prilocaine
         </a>
         ) [
         <a href="#rid92">
          92,103
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         hydrochloride 3% cream [
         <a href="#rid19">
          19
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10278" href="/z/d/drug information/10278.html" rel="external">
          Tetracaine
         </a>
         4% gel [
         <a href="#rid104">
          104
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          Morphine
         </a>
         0.3% gel [
         <a href="#rid105">
          105
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Locally infiltrative anesthetics
         </strong>
         – Local
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         injections, as well as tumescent anesthesia containing lidocaine, have been used to control the pain associated with MAL-PDT in the treatment of Gorlin syndrome [
         <a href="#rid33">
          33
         </a>
         ].
         <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">
          Mepivacaine
         </a>
         1% injected intraorally has been used for the treatment of actinic cheilitis with PDT [
         <a href="#rid106">
          106
         </a>
         ]. Successful pain control has also been reported with locally injected 0.5% lignocaine and adrenaline or a
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         /adrenaline mixture [
         <a href="#rid107">
          107
         </a>
         ]. Lidocaine has no adverse effect on ALA-PDT therapeutic outcomes, at least in vitro [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nerve block
         </strong>
         – Nerve blocks administered approximately 10 to 15 minutes prior to PDT reduce severe, intractable pain when treating extensive actinic keratoses (AKs) on the face and scalp without affecting the clinical outcome [
         <a href="#rid109">
          109-112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic analgesia
         </strong>
         – Significant pain reduction during PDT has been observed with the application of an inhaled
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         /oxygen mixture [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interrupted illumination
         </strong>
         – Delivering continuous light in two separate sessions with a three-minute intermission, in combination with cool water/pack application, has been shown to reduce PDT pain scores [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lower irradiance/daylight-mediated PDT
         </strong>
         – Although longer exposure times are required, daylight PDT is essentially painless [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="local">
          'Daylight photodynamic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Two-step irradiance
         </strong>
         – Pain can be minimized by administering red light at a low irradiance until the majority of PPIX is photobleached and then increasing to a higher irradiance until the total light dose is reached [
         <a href="#rid115">
          115
         </a>
         ]. For example, an initial irradiance of 30 to 50 mW/cm
         <sup>
          2
         </sup>
         for 20 J/cm
         <sup>
          2
         </sup>
         followed by 150 mW/cm
         <sup>
          2
         </sup>
         for a total fluence of 200 to 300 J/cm
         <sup>
          2
         </sup>
         has been used in the treatment of basal cell carcinoma and Bowen's disease [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          "In-office painless PDT"
         </strong>
         – In a prospective split-face study, utilizing 15-minute ALA incubation followed by 60 minutes of continuous blue light exposure resulted in a 52 percent reduction of facial AK lesions with a maximum pain score of only 2 out of 10 [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another prospective, split-face study, topical ALA 20% was applied to the entire face or scalp, and one side was illuminated with blue light immediately (no preincubation with illumination for either 30, 45, or 60 minutes) while the contralateral side received a conventional blue light regimen (one hour ALA incubation with illumination for 16 minutes and 40 seconds) [
         <a href="#rid77">
          77
         </a>
         ]. On the "conventional" side, pain evaluated on a 0 to 10 scale was 4 to 5 as compared with 0.5 to 1 on the "immediate illumination" side. Of note, AK lesion clearance was similar for all three painless regimens, suggesting that a 30-minute, simultaneous ALA/blue light regimen may be an effective, practical, and nearly painless option for facial and scalp AK [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3356058508">
         <span class="h2">
          Pain relief after treatment
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical corticosteroids
         </strong>
         – Potent topical corticosteroid application just before and after PDT was found to decrease post-treatment erythema without compromising efficacy [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic antihistamines
         </strong>
         – In a small randomized trial, H1 antihistamines, while not affecting the treatment outcome, were not found to be helpful in relieving post-therapy pain and inflammation [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2560807700">
         <span class="h1">
          AFTERCARE
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients are advised to remain indoors during daylight hours and to avoid bright indoor light for 48 hours after treatment. While indoors, they should stay away from large windows in order to avoid ambient light.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The area should be gently washed twice daily with a gentle facial cleanser. After cleansing, a bland emollient, such as a petroleum jelly with or without
         <a class="drug drug_general" data-topicid="101844" href="/z/d/drug information/101844.html" rel="external">
          lanolin
         </a>
         , can be applied to keep the area moist and free of crust.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the skin is irritated or pruritic, a topical corticosteroid ointment can be used once or twice daily for a few days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cool compresses can be applied for comfort as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By day 4 after treatment, tenderness of the skin should be improved, and twice-daily gentle exfoliation with a soft washcloth and warm water can be initiated. Follow with emollient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shaving of the treated areas should be avoided for several days after treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If patients must go outdoors, a thick, opaque coat of physical sunscreen (zinc or titanium dioxide), a wide-brimmed hat, and opaque clothing are recommended.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4047316752">
         <span class="h1">
          CONTRAINDICATIONS TO PHOTODYNAMIC THERAPY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known hypersensitivity to any of the components of the topical photosensitizer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known hypersensitivity to porphyrins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Porphyria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Photodermatoses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy or breastfeeding – There are no data available on the use of PDT in this patient population, although systemic absorption of
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         is thought to be negligible following topical administration [
         <a href="#rid54">
          54,55,57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children – Although the safety and efficacy of PDT in pediatric patients have not been established, PDT has been used for a variety of skin diseases in children [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H879749252">
         <span class="h1">
          PATIENT EDUCATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be educated prior to the treatment visit about what to expect before, during, and after PDT. An example of handout for patients is shown in the table  (
         <a class="graphic graphic_table graphicRef113755" href="/z/d/graphic/113755.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2985185132">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121040.html" rel="external">
          "Society guideline links: Photodynamic therapy for actinic keratosis and nonmelanoma skin cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1899633034">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and principles
         </strong>
         – Photodynamic therapy (PDT) is a noninvasive, nonscarring treatment most frequently used for the treatment of nonmelanoma skin cancer and precancerous lesions. PDT involves the application to the skin of a topical prodrug containing aminolevulinate that is converted to protoporphyrin IX (PPIX) within target cancer or precancer cells, followed by illumination with red or blue light to activate the PPIX. The photoactivation of PPIX by wavelengths of light within the visible spectrum, in the presence of oxygen, results in the death of the target cells. (See
         <a class="local">
          'Principles and mechanisms'
         </a>
         above and
         <a class="local">
          'Light sources'
         </a>
         above and
         <a class="local">
          'Topical photosensitizing medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – PDT is approved by the US Food and Drug Administration (FDA) for the treatment of thin, nonhyperkeratotic actinic keratosis (AK) of the scalp and face. In Europe, Canada, and other countries worldwide, PDT is also approved for the treatment of superficial and thin nodular basal cell carcinoma, when other available therapies are not acceptable, and squamous cell carcinoma in situ. PDT is used off label for the treatment of several skin conditions  (
         <a class="graphic graphic_table graphicRef113758" href="/z/d/graphic/113758.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Standard and modified regimens
         </strong>
         – Standard PDT regimens are available for the treatment of AK on the face and scalp, but these regimens may need to be modified depending on the patient or the skin disease being treated. (See
         <a class="local">
          'Standard photodynamic therapy regimens for actinic keratoses'
         </a>
         above and
         <a class="local">
          'Variations on the standard photodynamic therapy regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain control
         </strong>
         – Although a short-term side effect, pain associated with PDT can limit its use. Therefore, efforts should be made to enhance patient comfort during and after treatment without decreasing the therapeutic response. (See
         <a class="local">
          'Pain control measures'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Hasan T, Ortel B, Moor AC, Pogue BW. Photodynamic therapy of cancer. In: Cancer Medicine, 9th ed, Kufe D, Pollock RE, Weichselbaum RR, et al (Eds), B.C. Decker, 2017. p.537.
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacCormack MA. Photodynamic therapy. Adv Dermatol 2006; 22:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juzeniene A, Peng Q, Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci 2007; 6:1234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992; 14:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand S, Ortel BJ, Pereira SP, et al. Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett 2012; 326:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand S, Wilson C, Hasan T, Maytin EV. Vitamin D3 enhances the apoptotic response of epithelial tumors to aminolevulinate-based photodynamic therapy. Cancer Res 2011; 71:6040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand S, Rollakanti KR, Brankov N, et al. Fluorouracil Enhances Photodynamic Therapy of Squamous Cell Carcinoma via a p53-Independent Mechanism that Increases Protoporphyrin IX levels and Tumor Cell Death. Mol Cancer Ther 2017; 16:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rollakanti K, Anand S, Maytin EV. Topical calcitriol prior to photodynamic therapy enhances treatment efficacy in non-melanoma skin cancer mouse models. Proc SPIE Int Soc Opt Eng 2015; 9308:93080Q.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren CB, Lohser S, Wene LC, et al. Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate. J Biomed Opt 2010; 15:051607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rollakanti KR, Anand S, Davis SC, et al. Noninvasive Optical Imaging of UV-Induced Squamous Cell Carcinoma in Murine Skin: Studies of Early Tumor Development and Vitamin D Enhancement of Protoporphyrin IX Production. Photochem Photobiol 2015; 91:1469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karrer S, Bosserhoff AK, Weiderer P, et al. Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts. J Invest Dermatol 2003; 120:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karrer S, Bosserhoff AK, Weiderer P, et al. Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. Br J Dermatol 2004; 151:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004; 140:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinhold U, Dirschka T, Ostendorf R, et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED lamp. Br J Dermatol 2016; 175:696.
          </a>
         </li>
         <li class="breakAll">
          Levulan Kerastick (aminolevulinic acid HCl) for topical solution, 20%. US FDA approved product information; Wilmington, MA: DUSA Pharmaceuticals; March 2018. www.accessdata.fda.gov/drugsatfda_docs/label/2018/020965s015lbl.pdf (Accessed on April 05, 2018).
         </li>
         <li class="breakAll">
          www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous (Accessed on June 29, 2017).
         </li>
         <li class="breakAll">
          Metvixia (methyl aminolevulinate) Cream, 16.8%. US FDA approved product information; Oslo, Norway: Photocure ASA; June 2008. www.accessdata.fda.gov/drugsatfda_docs/label/2008/021415s003lbl.pdf (Accessed on June 27, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pariser DM, Houlihan A, Ferdon MB, et al. Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp. Dermatol Surg 2016; 42:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touma D, Yaar M, Whitehead S, et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004; 140:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. JAMA Dermatol 2014; 150:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev 2012; 12:CD004415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol 2011; 25:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosgarea R, Susan M, Crisan M, Senila S. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol 2012; 167:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22:1302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008; 159:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Q, Gao T, Jiao B, et al. Tumor thickness predicts long-term complete response of facial basal cell carcinomas in Asian skin types iv/v treated with methyl aminolaevulinate photodynamic therapy. Photomed Laser Surg 2011; 29:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basset-Seguin N, Bissonnette R, Girard C, et al. Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. J Eur Acad Dermatol Venereol 2014; 28:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauwels C, Mazereeuw-Hautier J, Basset-Seguin N, et al. Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures. J Eur Acad Dermatol Venereol 2011; 25:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girard C, Debu A, Bessis D, et al. Treatment of Gorlin syndrome (nevoid basal cell carcinoma syndrome) with methylaminolevulinate photodynamic therapy in seven patients, including two children: interest of tumescent anesthesia for pain control in children. J Eur Acad Dermatol Venereol 2013; 27:e171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loncaster J, Swindell R, Slevin F, et al. Efficacy of photodynamic therapy as a treatment for Gorlin syndrome-related basal cell carcinomas. Clin Oncol (R Coll Radiol) 2009; 21:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loncaster JA, Allan E. Photodynamic therapy in the management of a patient with Gorlin syndrome (naevoid basal cell carcinoma syndrome). Photodiagnosis Photodyn Ther 2006; 3:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mougel F, Debarbieux S, Ronger-Savlé S, et al. Methylaminolaevulinate photodynamic therapy in patients with multiple basal cell carcinomas in the setting of Gorlin-Goltz syndrome or after radiotherapy. Dermatology 2009; 219:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol 2006; 142:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehmann P. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol 2007; 156:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol 2008; 159:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truchuelo M, Fernández-Guarino M, Fleta B, et al. Effectiveness of photodynamic therapy in Bowen's disease: an observational and descriptive study in 51 lesions. J Eur Acad Dermatol Venereol 2012; 26:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souza CS, Felicio LB, Ferreira J, et al. Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for non-melanoma skin cancer. Photodiagnosis Photodyn Ther 2009; 6:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilaberte Y, Milla L, Salazar N, et al. Cellular intrinsic factors involved in the resistance of squamous cell carcinoma to photodynamic therapy. J Invest Dermatol 2014; 134:2428.
          </a>
         </li>
         <li class="breakAll">
          www.dusapharma.com/blu-u1.html (Accessed on June 12, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor M. Photodynamic therapy for acne: are we there yet? Br J Dermatol 2016; 174:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keyal U, Bhatta AK, Wang XL. Photodynamic therapy for the treatment of different severity of acne: A systematic review. Photodiagnosis Photodyn Ther 2016; 14:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma Y, Chen Q, Liu Y, et al. Effects of 5-aminolevulinic acid photodynamic therapy on TLRs in acne lesions and keratinocytes co-cultured with P. acnes. Photodiagnosis Photodyn Ther 2016; 15:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hörfelt C, Funk J, Frohm-Nilsson M, et al. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006; 155:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu LH, Fan X, An YX, et al. Randomized trial of three phototherapy methods for the treatment of acne vulgaris in Chinese patients. Photodermatol Photoimmunol Photomed 2014; 30:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakamoto FH, Torezan L, Anderson RR. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol 2010; 63:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karrer S, Kohl E, Feise K, et al. Photodynamic therapy for skin rejuvenation: review and summary of the literature--results of a consensus conference of an expert group for aesthetic photodynamic therapy. J Dtsch Dermatol Ges 2013; 11:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Rodriguez R, Sanz-Sánchez T, Córdoba S. Photodynamic photorejuvenation. Dermatol Surg 2002; 28:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dover JS, Bhatia AC, Stewart B, Arndt KA. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol 2005; 141:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold MH, Bradshaw VL, Boring MM, et al. Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage. Dermatol Surg 2006; 32:795.
          </a>
         </li>
         <li class="breakAll">
          Levulan Kerastick [prescribing information]. Wilmington, MA: DUSA Pharmaceuticals, Inc.; 2010.
         </li>
         <li class="breakAll">
          Ameluz [prescribing information]. Wakefield, MA: Biofrontera Inc.; 2016.
         </li>
         <li class="breakAll">
          www.biofrontera.us.com/for-healthcare-professionals/bf-rhodoled/using-bf-rhodoled/ (Accessed on June 12, 2017).
         </li>
         <li class="breakAll">
          Metvixia [pacakge insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heusinkveld LE, Bullock TA, Negrey J, et al. Sandpaper curettage: A simple method to improve PDT outcomes for actinic keratosis. Photodiagnosis Photodyn Ther 2022; 40:103050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bencini PL, Galimberti MG, Pellacani G, Longo C. Application of photodynamic therapy combined with pre-illumination microneedling in the treatment of actinic keratosis in organ transplant recipients. Br J Dermatol 2012; 167:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torezan L, Chaves Y, Niwa A, et al. A pilot split-face study comparing conventional methyl aminolevulinate-photodynamic therapy (PDT) with microneedling-assisted PDT on actinically damaged skin. Dermatol Surg 2013; 39:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer JM, Freeman SA. Microneedling Prior to Levulan PDT for the Treatment of Actinic Keratoses: A Split-Face, Blinded Trial. J Drugs Dermatol 2016; 15:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petukhova TA, Hassoun LA, Foolad N, et al. Effect of Expedited Microneedle-Assisted Photodynamic Therapy for Field Treatment of Actinic Keratoses: A Randomized Clinical Trial. JAMA Dermatol 2017; 153:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Togsverd-Bo K, Haak CS, Thaysen-Petersen D, et al. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial. Br J Dermatol 2012; 166:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haak CS, Christiansen K, Erlendsson AM, et al. Ablative fractional laser enhances MAL-induced PpIX accumulation: Impact of laser channel density, incubation time and drug concentration. J Photochem Photobiol B 2016; 159:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bay C, Lerche CM, Ferrick B, et al. Comparison of Physical Pretreatment Regimens to Enhance Protoporphyrin IX Uptake in Photodynamic Therapy: A Randomized Clinical Trial. JAMA Dermatol 2017; 153:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmieder GJ, Huang EY, Jarratt M. A multicenter, randomized, vehicle-controlled phase 2 study of blue light photodynamic therapy with aminolevulinic acid HCl 20% topical solution for the treatment of actinic keratoses on the upper extremities: the effect of occlusion during the drug incubation period. J Drugs Dermatol 2012; 11:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bissonnette R, Bolduc C, Maari C, Nigen S. Short incubation photodynamic therapy with methylaminolevulinate and no occlusion for the treatment of actinic keratoses. J Am Acad Dermatol 2012; 67:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishida N, Watanabe D, Mizutani K, et al. Heating increases protoporphyrin IX production in normal skin after delivery of 5-aminolevulinic acid by iontophoresis. Photodermatol Photoimmunol Photomed 2009; 25:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willey A, Anderson RR, Sakamoto FH. Temperature-Modulated Photodynamic Therapy for the Treatment of Actinic Keratosis on the Extremities: A One-Year Follow-up Study. Dermatol Surg 2015; 41:1290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uehlinger P, Ballini JP, van den Bergh H, Wagnières G. On the role of iron and one of its chelating agents in the production of protoporphyrin IX generated by 5-aminolevulinic acid and its hexyl ester derivative tested on an epidermal equivalent of human skin. Photochem Photobiol 2006; 82:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell SM, Morton CA, Alyahya R, et al. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol 2008; 159:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand S, Honari G, Hasan T, et al. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res 2009; 15:3333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maytin EV, Anand S, Riha M, et al. 5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial. Clin Cancer Res 2018; 24:3026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bullock TA, Negrey J, Hu B, et al. Significant improvement of facial actinic keratoses after blue light photodynamic therapy with oral vitamin D pretreatment: An interventional cohort-controlled trial. J Am Acad Dermatol 2022; 87:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin GM. In-office Painless Aminolevulinic Acid Photodynamic Therapy: A Proof of Concept Study and Clinical Experience in More Than 100 Patients. J Clin Aesthet Dermatol 2016; 9:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gandy J, Labadie B, Bierman D, Zachary C. Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time. J Drugs Dermatol 2017; 16:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaw U, Ilyas M, Bullock T, et al. A regimen to minimize pain during blue light photodynamic therapy of actinic keratoses: Bilaterally controlled, randomized trial of simultaneous versus conventional illumination. J Am Acad Dermatol 2020; 82:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiegell SR, Haedersdal M, Philipsen PA, et al. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol 2008; 158:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiegell SR, Wulf HC, Szeimies RM, et al. Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012; 26:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane KL, Hovenic W, Ball K, Zachary CB. Daylight photodynamic therapy: the Southern California experience. Lasers Surg Med 2015; 47:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glazer-Hockstein C, Dunaief JL. Could blue light-blocking lenses decrease the risk of age-related macular degeneration? Retina 2006; 26:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barkana Y, Belkin M. Laser eye injuries. Surv Ophthalmol 2000; 44:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter JJ, Morgan JI, Merigan WH, et al. The susceptibility of the retina to photochemical damage from visible light. Prog Retin Eye Res 2012; 31:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vassileva SG, Mateev G, Parish LC. Antimicrobial photosensitive reactions. Arch Intern Med 1998; 158:1993.
          </a>
         </li>
         <li class="breakAll">
          Levulan Kerastick (aminolevulinic acid HCl) for topical solution, 20%. US FDA approved product information; Wilmington, MA: DUSA Pharmaceuticals; April 2018. www.accessdata.fda.gov/drugsatfda_docs/label/2018/020965s016lbl.pdf (Accessed on May 11, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babilas P, Schreml S, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology: state-of-the-art. Photodermatol Photoimmunol Photomed 2010; 26:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe CM, Hatfield K, Cognetta AB Jr. Cellulitis as a postprocedural complication of topical 5-aminolevulinic acid photodynamic therapy in the treatment of actinic keratosis. J Drugs Dermatol 2007; 6:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribeiro CF, Souza FH, Jordão JM, et al. Photodynamic therapy in actinic cheilitis: clinical and anatomopathological evaluation of 19 patients. An Bras Dermatol 2012; 87:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinbauer J, Schreml S, Karrer S, et al. Phototoxic reactions in healthy volunteers following photodynamic therapy with methylaminolevulinate cream or with cream containing 5-aminolevulinic acid: a phase II, randomized study. Photodermatol Photoimmunol Photomed 2009; 25:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren CB, Karai LJ, Vidimos A, Maytin EV. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. J Am Acad Dermatol 2009; 61:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babes A, Sauer SK, Moparthi L, et al. Photosensitization in Porphyrias and Photodynamic Therapy Involves TRPA1 and TRPV1. J Neurosci 2016; 36:5264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grapengiesser S, Ericson M, Gudmundsson F, et al. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halldin CB, Gillstedt M, Paoli J, et al. Predictors of pain associated with photodynamic therapy: a retrospective study of 658 treatments. Acta Derm Venereol 2011; 91:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fritsch C, Stege H, Saalmann G, et al. Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses. Photodermatol Photoimmunol Photomed 1997; 13:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morton CA, Whitehurst C, Moore JV, MacKie RM. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000; 143:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasche A, Luderschmidt S, Ring J, Hein R. Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J Drugs Dermatol 2006; 5:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol 2007; 157:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiegell SR, Stender IM, Na R, Wulf HC. Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol 2003; 139:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol 2006; 54:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagliaro J, Elliott T, Bulsara M, et al. Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen's disease: an effective addition to treatment: a pilot study. Dermatol Surg 2004; 30:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stangeland KZ, Kroon S. Cold air analgesia as pain reduction during photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol 2012; 26:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyrrell J, Campbell SM, Curnow A. The effect of air cooling pain relief on protoporphyrin IX photobleaching and clinical efficacy during dermatological photodynamic therapy. J Photochem Photobiol B 2011; 103:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langan SM, Collins P. Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutetic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolaevulinic acid-photodynamic therapy for extensive scalp actinic keratoses. Br J Dermatol 2006; 154:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes MV, Dawe RS, Ferguson J, Ibbotson SH. A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy. Br J Dermatol 2004; 150:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skiveren J, Haedersdal M, Philipsen PA, et al. Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. Acta Derm Venereol 2006; 86:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berking C, Herzinger T, Flaig MJ, et al. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg 2007; 33:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wennberg AM. Pain, pain relief and other practical issues in photodynamic therapy. Australas J Dermatol 2005; 46 Suppl 3:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikolajewska P, Juzeniene A, Moan J. The effect of lidocaine on PpIX photobleaching and outcome of ALA-PDT in vitro. Photodiagnosis Photodyn Ther 2007; 4:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paoli J, Halldin C, Ericson MB, Wennberg AM. Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol 2008; 33:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein A, Karrer S, Horner C, et al. Comparing cold-air analgesia, systemically administered analgesia and scalp nerve blocks for pain management during photodynamic therapy for actinic keratosis of the scalp presenting as field cancerization: a randomized controlled trial. Br J Dermatol 2015; 173:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halldin CB, Paoli J, Sandberg C, et al. Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Br J Dermatol 2009; 160:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serra-Guillen C, Hueso L, Nagore E, et al. Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratoses of the frontotemporal zone. Br J Dermatol 2009; 161:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fink C, Uhlmann L, Enk A, Gholam P. Pain management in photodynamic therapy using a nitrous oxide/oxygen mixture: a prospective, within-patient, controlled clinical trial. J Eur Acad Dermatol Venereol 2017; 31:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiegell SR, Haedersdal M, Wulf HC. Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study. Acta Derm Venereol 2009; 89:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottrell WJ, Paquette AD, Keymel KR, et al. Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin Cancer Res 2008; 14:4475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeitouni NC, Paquette AD, Housel JP, et al. A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. Lasers Surg Med 2013; 45:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiegell SR, Petersen B, Wulf HC. Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. Br J Dermatol 2014; 171:1487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanaman Wilson MJ, Jones IT, Wu DC, Goldman MP. A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy. Lasers Surg Med 2017; 49:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar N, Warren CB. Photodynamic therapy for dermatologic conditions in the pediatric population: a literature review. Photodermatol Photoimmunol Photomed 2017; 33:125.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13647 Version 11.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hasan T, Ortel B, Moor AC, Pogue BW. Photodynamic therapy of cancer. In: Cancer Medicine, 9th ed, Kufe D, Pollock RE, Weichselbaum RR, et al (Eds), B.C. Decker, 2017. p.537.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17249304" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18046478" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Milestones in the development of photodynamic therapy and fluorescence diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1403373" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22842096" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Biomodulatory approaches to photodynamic therapy for solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21807844" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Vitamin D3 enhances the apoptotic response of epithelial tumors to aminolevulinate-based photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28336806" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Fluorouracil Enhances Photodynamic Therapy of Squamous Cell Carcinoma via a p53-Independent Mechanism that Increases Protoporphyrin IX levels and Tumor Cell Death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25983370" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Topical calcitriol prior to photodynamic therapy enhances treatment efficacy in non-melanoma skin cancer mouse models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21054081" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26223149" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Noninvasive Optical Imaging of UV-Induced Squamous Cell Carcinoma in Murine Skin: Studies of Early Tumor Development and Vitamin D Enhancement of Protoporphyrin IX Production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12542540" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15491416" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14732659" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26921093" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED lamp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26921093" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED lamp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26921093" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED lamp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26921093" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED lamp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26863596" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14732657" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25162181" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23235610" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Interventions for actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21054566" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23683751" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22738399" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22612571" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18624836" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18693158" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17875873" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18717680" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21456944" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Tumor thickness predicts long-term complete response of facial basal cell carcinomas in Asian skin types iv/v treated with methyl aminolaevulinate photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23581795" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21668511" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22500823" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Treatment of Gorlin syndrome (nevoid basal cell carcinoma syndrome) with methylaminolevulinate photodynamic therapy in seven patients, including two children: interest of tumescent anesthesia for pain control in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19398312" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy of photodynamic therapy as a treatment for Gorlin syndrome-related basal cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25049106" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Photodynamic therapy in the management of a patient with Gorlin syndrome (naevoid basal cell carcinoma syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19590166" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Methylaminolaevulinate photodynamic therapy in patients with multiple basal cell carcinomas in the setting of Gorlin-Goltz syndrome or after radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16785375" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17419691" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18489606" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21740466" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effectiveness of photodynamic therapy in Bowen's disease: an observational and descriptive study in 51 lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19932453" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for non-melanoma skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24717244" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cellular intrinsic factors involved in the resistance of squamous cell carcinoma to photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24717244" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cellular intrinsic factors involved in the resistance of squamous cell carcinoma to photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27115580" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Photodynamic therapy for acne: are we there yet?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27090488" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Photodynamic therapy for the treatment of different severity of acne: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27421917" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effects of 5-aminolevulinic acid photodynamic therapy on TLRs in acne lesions and keratinocytes co-cultured with P. acnes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16911289" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24313686" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Randomized trial of three phototherapy methods for the treatment of acne vulgaris in Chinese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20633797" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23190505" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Photodynamic therapy for skin rejuvenation: review and summary of the literature--results of a consensus conference of an expert group for aesthetic photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12174070" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Photodynamic photorejuvenation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16230562" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16792644" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16792644" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16792644" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16792644" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16792644" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35932960" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Sandpaper curettage: A simple method to improve PDT outcomes for actinic keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22578273" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Application of photodynamic therapy combined with pre-illumination microneedling in the treatment of actinic keratosis in organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23638986" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A pilot split-face study comparing conventional methyl aminolevulinate-photodynamic therapy (PDT) with microneedling-assisted PDT on actinically damaged skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27602968" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Microneedling Prior to Levulan PDT for the Treatment of Actinic Keratoses: A Split-Face, Blinded Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28514458" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Effect of Expedited Microneedle-Assisted Photodynamic Therapy for Field Treatment of Actinic Keratoses: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22348388" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27016718" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Ablative fractional laser enhances MAL-induced PpIX accumulation: Impact of laser channel density, incubation time and drug concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28146245" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Comparison of Physical Pretreatment Regimens to Enhance Protoporphyrin IX Uptake in Photodynamic Therapy: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23377520" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A multicenter, randomized, vehicle-controlled phase 2 study of blue light photodynamic therapy with aminolevulinic acid HCl 20% topical solution for the treatment of actinic keratoses on the upper extremities: the effect of occlusion during the drug incubation period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23158619" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Short incubation photodynamic therapy with methylaminolevulinate and no occlusion for the treatment of actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19906171" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Heating increases protoporphyrin IX production in normal skin after delivery of 5-aminolevulinic acid by iontophoresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26445287" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Temperature-Modulated Photodynamic Therapy for the Treatment of Actinic Keratosis on the Extremities: A One-Year Follow-up Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17205631" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : On the role of iron and one of its chelating agents in the production of protoporphyrin IX generated by 5-aminolevulinic acid and its hexyl ester derivative tested on an epidermal equivalent of human skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18544077" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19447864" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29593028" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : 5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35314199" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Significant improvement of facial actinic keratoses after blue light photodynamic therapy with oral vitamin D pretreatment: An interventional cohort-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27047629" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : In-office Painless Aminolevulinic Acid Photodynamic Therapy: A Proof of Concept Study and Clinical Experience in More Than 100 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28301624" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31525441" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A regimen to minimize pain during blue light photodynamic therapy of actinic keratoses: Bilaterally controlled, randomized trial of simultaneous versus conventional illumination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18294318" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22211665" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25663047" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Daylight photodynamic therapy: the Southern California experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16395131" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Could blue light-blocking lenses decrease the risk of age-related macular degeneration?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10906379" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Laser eye injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22085795" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The susceptibility of the retina to photochemical damage from visible light.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9778198" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Antimicrobial photosensitive reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9778198" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Antimicrobial photosensitive reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20584250" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Photodynamic therapy in dermatology: state-of-the-art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17679192" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Cellulitis as a postprocedural complication of topical 5-aminolevulinic acid photodynamic therapy in the treatment of actinic keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22714758" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Photodynamic therapy in actinic cheilitis: clinical and anatomopathological evaluation of 19 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19747247" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Phototoxic reactions in healthy volunteers following photodynamic therapy with methylaminolevulinate cream or with cream containing 5-aminolevulinic acid: a phase II, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19925929" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Pain associated with aminolevulinic acid-photodynamic therapy of skin disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27170124" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Photosensitization in Porphyrias and Photodynamic Therapy Involves TRPA1 and TRPV1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12372093" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Pain caused by photodynamic therapy of skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21611684" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Predictors of pain associated with photodynamic therapy: a retrospective study of 658 treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9542754" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11069454" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16673803" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17501954" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12975159" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16546587" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14692930" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen's disease: an effective addition to treatment: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21707775" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Cold air analgesia as pain reduction during photodynamic therapy of actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21277787" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The effect of air cooling pain relief on protoporphyrin IX photobleaching and clinical efficacy during dermatological photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16403108" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutetic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolaevulinic acid-photodynamic therapy for extensive scalp actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14996106" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16955184" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17598848" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15859299" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Pain, pain relief and other practical issues in photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25047561" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : The effect of lidocaine on PpIX photobleaching and outcome of ALA-PDT in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18801096" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25413485" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Comparing cold-air analgesia, systemically administered analgesia and scalp nerve blocks for pain management during photodynamic therapy for actinic keratosis of the scalp presenting as field cancerization: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19210497" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19438468" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratoses of the frontotemporal zone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27393707" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Pain management in photodynamic therapy using a nitrous oxide/oxygen mixture: a prospective, within-patient, controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19325998" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18628462" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23390058" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25060803" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28489298" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28130791" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Photodynamic therapy for dermatologic conditions in the pediatric population: a literature review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
